PITOLISANT HYDROCHLORIDE - Generic Drug Details

What are the generic sources for pitolisant hydrochloride and what is the scope of freedom to operate?

Pitolisant hydrochloride is the generic ingredient in one branded drug marketed by Harmony and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pitolisant hydrochloride has sixty-one patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for PITOLISANT HYDROCHLORIDE

International Patents:	61
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	32
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PITOLISANT HYDROCHLORIDE
What excipients (inactive ingredients) are in PITOLISANT HYDROCHLORIDE?	PITOLISANT HYDROCHLORIDE excipients list
DailyMed Link:	PITOLISANT HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PITOLISANT HYDROCHLORIDE

Constraining patent/regulatory exclusivity:

TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH NARCOLEPSY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PITOLISANT HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Harmony Biosciences Management, Inc.	PHASE1
Harmony Biosciences Management, Inc.	PHASE3
Bioprojet	PHASE2

See all PITOLISANT HYDROCHLORIDE clinical trials

Pharmacology for PITOLISANT HYDROCHLORIDE

Drug Class	Histamine-3 Receptor Antagonist/Inverse Agonist
Mechanism of Action	Cytochrome P450 3A4 Inducers Histamine H3 Receptor Antagonists Histamine H3 Receptor Inverse Agonists

Anatomical Therapeutic Chemical (ATC) Classes for PITOLISANT HYDROCHLORIDE

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for PITOLISANT HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WAKIX	Tablets	pitolisant hydrochloride	4.45 mg and 17.8 mg	211150	7	2023-08-14

US Patents and Regulatory Information for PITOLISANT HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019		RX	Yes	Yes
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No	8,354,430
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No

Expired US Patents for PITOLISANT HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019	7,169,928
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019	7,910,605
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019	8,354,430
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019	7,169,928

International Patents for PITOLISANT HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
South Korea	20070101381	MONOHYDROCHLORIDE SALT OF 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE
Serbia	52911	LEČENJE SIMPTOMA PARKINSONOVE BOLESTI SA ALKILAMIN HISTAMINOM BEZ IMIDAZOLA - X3 - RECEPTORA LIGANDA (TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS)
New Zealand	561940	Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
Slovenia	1863487

Supplementary Protection Certificates for PITOLISANT HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1428820	40/2016	Austria		PRODUCT NAME: PITOLISANT UND SEINE PHARMAZEUTISCH VERTRAEGLICHEN SALZE EINSCHLIESSLICH DEM HYDROCHLORID; REGISTRATION NO/DATE: EU/1/15/1068 (MITTEILUNG) 20160404
1428820	300832	Netherlands		PRODUCT NAME: PITOLISANT EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN, ZOALS HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/15/1068/002 20160404
1428820	2016/038	Ireland		PRODUCT NAME: PITOLISANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SUCH AS HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/15/1068 20160331
1428820	2016C/048	Belgium		PRODUCT NAME: PITOLISANT ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES TELS QUE LE CHLORHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1068 20160404

Pitolisant Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 16, 2026

Overview

Pitolisant hydrochloride (brand name: Wakix), developed by Harmony Biosciences, is a histamine H3 receptor inverse agonist approved in 2019 by the FDA for excessive daytime sleepiness associated with narcolepsy. Its launch marked a notable entry into the wake-promoting drug segment, reflecting shifts in treatment options for sleep disorders. Its market progression combines legislative, clinical, competitive, and commercial factors that influence its financial trajectory.

Market Size and Growth Trends

The global narcolepsy treatment market was valued at approximately USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2030, reaching USD 2.2 billion. The segment includes stimulants, sodium oxybate, and emerging drugs like pitolisant.

Pitolisant’s potential market share is constrained by several factors, including availability of established treatments and regulatory scope. It primarily targets the narcolepsy segment, which accounts for roughly 75% of the overall sleep disorder pharmaceuticals market.

Key Drivers

1. FDA and Global Approvals: Following FDA approval, the drug has gained regulatory clearances in the European Union (EMA approval in 2016) and Japan (2019). These approvals expand its market reach but also involve regional regulatory challenges.

2. Unmet Needs: Few effective non-stimulant options exist for narcolepsy, particularly for patients who cannot tolerate stimulants. Pitolisant offers a non-amphetamine-based alternative, appealing to both physicians and patients concerned with abuse potential.

3. Clinical Data: Trials demonstrate improved wakefulness scores and reduced cataplexy in narcoleptic patients, bolstering its position especially for narcolepsy with cataplexy. Additional indications are under investigation, including excessive daytime sleepiness in Parkinson’s disease.

4. Pricing and Reimbursement: Initial US pricing was set around USD 420 per month, positioning it as a premium but competitive option. Reimbursement policies are evolving, with payers considering cost-effectiveness compared to stimulants and sodium oxybate.

Competitive Landscape

• Stimulants: Drugs like modafinil (Provigil) and methylphenidate dominate the market, with combined sales exceeding USD 1 billion annually. They benefit from established prescribing habits but face regulatory scrutiny and abuse concerns.
• Sodium Oxybate (Xyrem): Marketed for narcolepsy with cataplexy, with sales surpassing USD 700 million globally. It has logistical restrictions and strict regulations.
• Emerging Therapies: Solriamfetol (Sunosi), approved in 2019, offers another non-stimulant option, with similar efficacy and pricing, increasing competition.

Financial Trajectory

Sales projections for pitolisant hinge on several factors:

Factor	Impact
Market Penetration	With limited awareness, initial uptake may be slow. Expect 5-10% share in narcolepsy treatment by 2025.
Regional Expansion	US and EU remain primary markets; Japan and emerging markets contribute growth. Expansion could double addressable market size by 2027.
Prescriber Adoption	Education campaigns and insurance coverage influence prescribing rates. Upward trends expected with positive clinical outcomes.
Patent and Exclusivity Period	Patent protection extends to 2027 in key markets. Generic entry anticipated thereafter, potentially reducing prices and profits.

Estimated revenue growth:

• 2023: USD 50-75 million in US sales.
• 2025: USD 150 million, accounting for increased recognition and expanded prescriber base.
• 2027: USD 300 million, assuming successful regional penetration.

Post-patent expiration (circa 2027), generic competition may lead to pricing reductions of 30-50%, impacting margins.

Regulatory and Policy Considerations

• The drug’s non-stimulant profile may favor inclusion in guidelines and tighter prescribing restrictions on stimulants.
• Reimbursement negotiations and formulary placements will be pivotal; regional variability heavily influences profitability.
• Ongoing clinical trials for secondary indications could broaden its use and revenue streams.

Risks and Challenges

1. Market Penetration: Entrenched prescribing patterns favoring stimulants and sodium oxybate may slow adoption.
2. Pricing Pressures: Payers aim for price reductions, impacting margins.
3. Regulatory Delays or Rejections: Additional approvals or label extensions depend on ongoing trial results and regulatory climate.
4. Generic Competition: Patent expiry and generic entry could dilute revenue streams.

Key Takeaways

• Pitolisant hydrochloride’s growth prospects depend on regional expansion, prescriber education, and payer acceptance.
• Market size is constrained by competition from established therapies but has growth potential through its non-stimulant profile.
• Revenue estimates suggest a gradual increase through 2025, with potential stabilization or decline post-2027 amid patent expiration.
• Regulatory environment and reimbursement strategies significantly influence financial success.
• The drug’s positioning as a non-stimulant option supports niche market growth but faces stiff competition.

FAQs

1. What limits pitolisant’s market penetration?
   Its growth faces barriers from entrenched stimulant usage, payer restrictions, and limited awareness among physicians.

2. How does pitolisant compare financially to competitors?
   It is priced similarly to solriamfetol but lower than sodium oxybate. Expected market share is low initially but could increase with broader acceptance.

3. What are the primary revenue drivers?
   Regional expansion, prescriber adoption, and clinical trial success for additional indications.

4. When will patent expiry affect profitability?
   Expected around 2027, after which generic versions could reduce revenues substantially.

5. Are there other regulatory hurdles?
   Potential delays relate to clinical trial outcomes, label extensions, and regional approval processes.

Citations

[1] MarketsandMarkets, "Sleep Disorder Drugs Market," 2022.
[2] FDA, "Wakix (pitolisant) prescribing information," 2019.
[3] IQVIA, "Global Narcolepsy Treatment Market Data," 2022.
[4] Harmony Biosciences, "Wakix US Launch Announcement," 2019.
[5] Reports on clinical trials and approvals from EMA and PMDA, 2016–2019.